XOMA Royalty (XOMA)

XOMA focuses largely on pre-commercial and clinical-stage assets, including early to mid-stage drug candidates where future value depends on development progress. This gives the company exposure to a broad set of potential therapies while leaving the scientific, regulatory, manufacturing, and commercial execution to its partners. Its portfolio can include rights connected to multiple therapeutic areas, sponsors, and geographies, which helps spread risk across a range of development programmes.

The company’s model is designed to serve both sides of the biotechnology market. Developers can obtain non-dilutive or less dilutive funding to support research and corporate priorities, while XOMA gains the possibility of long-term royalty income or milestone receipts. Because many of the underlying assets are not yet approved products, results can be influenced by clinical trial outcomes, regulatory decisions, partner priorities, and capital allocation across the pharmaceutical industry. XOMA operates with a global perspective, with interests associated with companies and programmes in the United States, Europe, Switzerland, Asia Pacific, and other regions.